Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 32
18
Diseases
59
Unique genes
0.234
Avg. similarity score
atypical hemolytic-uremic syndrome
Most-connected disease (10 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
atypical hemolytic-uremic syndrome
C3 glomerulonephritis
Mesangiocapillary glomerulonephritis
Thrombotic microangiopathy
Factor h deficiency
Genetic hemolytic uremic syndrome
Atypical hemolytic uremic syndrome
Factor i deficiency
Hemolytic uremic syndrome
Central serous retinopathy
Macular and posterior pole degeneration
Doyne honeycomb retinal dystrophy
Panuveitis
atypical hemolytic-uremic syndrome with B factor anomaly
DDX41-related hematologic malignancy predisposition syndrome
Intellectual developmental disorder seizures cerebellar
Throat disease
hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| atypical hemolytic-uremic syndrome | 10 | 10 | 3 |
| C3 glomerulonephritis | 7 | 7 | 8 |
| Mesangiocapillary glomerulonephritis | 7 | 7 | 8 |
| Thrombotic microangiopathy | 7 | 7 | 3 |
| Factor h deficiency | 6 | 6 | 1 |
| Genetic hemolytic uremic syndrome | 6 | 6 | 1 |
| Atypical hemolytic uremic syndrome | 5 | 5 | 2 |
| Factor i deficiency | 5 | 5 | 1 |
| Hemolytic uremic syndrome | 5 | 5 | 33 |
| Central serous retinopathy | 4 | 4 | 11 |
| Macular and posterior pole degeneration | 4 | 4 | 13 |
| Doyne honeycomb retinal dystrophy | 3 | 3 | 4 |
| Panuveitis | 3 | 3 | 2 |
| atypical hemolytic-uremic syndrome with B factor anomaly | 2 | 2 | 1 |
| DDX41-related hematologic malignancy predisposition syndrome | 1 | 1 | 1 |
| Intellectual developmental disorder seizures cerebellar | 1 | 1 | 1 |
| Throat disease | 1 | 1 | 3 |
| hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| CFH | 12 / 18 | Atypical hemolytic uremic syndrome, atypical hemolytic-uremic syndrome, C3 glomerulonephritis, Central serous retinopathy and 8 more |
| CFI | 8 / 18 | atypical hemolytic-uremic syndrome, C3 glomerulonephritis, Doyne honeycomb retinal dystrophy, Factor i deficiency and 4 more |
| CD46 | 5 / 18 | Atypical hemolytic uremic syndrome, atypical hemolytic-uremic syndrome, Hemolytic uremic syndrome, Macular and posterior pole degeneration and 1 more |
| C3 | 4 / 18 | C3 glomerulonephritis, Hemolytic uremic syndrome, Macular and posterior pole degeneration, Mesangiocapillary glomerulonephritis |
| CFB | 4 / 18 | atypical hemolytic-uremic syndrome with B factor anomaly, C3 glomerulonephritis, Hemolytic uremic syndrome, Mesangiocapillary glomerulonephritis |
| CFHR1 | 3 / 18 | C3 glomerulonephritis, Hemolytic uremic syndrome, Mesangiocapillary glomerulonephritis |
| CFHR5 | 3 / 18 | C3 glomerulonephritis, Hemolytic uremic syndrome, Mesangiocapillary glomerulonephritis |
| C1GALT1C1 | 2 / 18 | Hemolytic uremic syndrome, hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature |
| CFHR3 | 2 / 18 | C3 glomerulonephritis, Hemolytic uremic syndrome |
| DDX41 | 2 / 18 | DDX41-related hematologic malignancy predisposition syndrome, Thrombotic microangiopathy |
| DGKE | 2 / 18 | Hemolytic uremic syndrome, Mesangiocapillary glomerulonephritis |
| GATA5 | 2 / 18 | Central serous retinopathy, Throat disease |
| RORA | 2 / 18 | Central serous retinopathy, Intellectual developmental disorder seizures cerebellar |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Complement and coagulation cascades | KEGG | 14 / 88 | 32.4× | 4.46e-18 | 2.63e-15 ✓ sig. |
| Regulation of Complement cascade | Reactome | 11 / 47 | 47.6× | 2.28e-16 | 9.89e-14 ✓ sig. |
| Interleukin-10 signaling | Reactome | 6 / 47 | 26.0× | 9.95e-8 | 6.50e-6 ✓ sig. |
| Malaria | KEGG | 6 / 50 | 24.4× | 1.46e-7 | 9.06e-6 ✓ sig. |
| Staphylococcus aureus infection | KEGG | 7 / 99 | 14.4× | 5.02e-7 | 2.69e-5 ✓ sig. |
| Inflammatory bowel disease | KEGG | 6 / 66 | 18.5× | 7.83e-7 | 3.94e-5 ✓ sig. |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 7 / 108 | 13.2× | 9.08e-7 | 4.48e-5 ✓ sig. |
| African trypanosomiasis | KEGG | 5 / 37 | 27.5× | 9.30e-7 | 4.57e-5 ✓ sig. |
| Pertussis | KEGG | 6 / 78 | 15.7× | 2.12e-6 | 9.22e-5 ✓ sig. |
| Hematopoietic cell lineage | KEGG | 6 / 100 | 12.2× | 9.04e-6 | 3.09e-4 ✓ sig. |
| AGE-RAGE signaling pathway in diabetic complications | KEGG | 6 / 101 | 12.1× | 9.57e-6 | 3.24e-4 ✓ sig. |
| Amoebiasis | KEGG | 6 / 103 | 11.9× | 1.07e-5 | 3.56e-4 ✓ sig. |
| Coronavirus disease - COVID-19 | KEGG | 8 / 238 | 6.8× | 1.96e-5 | 5.89e-4 ✓ sig. |
| Leishmaniasis | KEGG | 5 / 78 | 13.0× | 3.86e-5 | 1.03e-3 ✓ sig. |
| Fluid shear stress and atherosclerosis | KEGG | 6 / 141 | 8.7× | 6.36e-5 | 1.55e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| complement activation | GO:0006956 | 11 / 35 | 99.5× | 4.55e-20 | 7.58e-17 ✓ sig. |
| complement activation, alternative pathway | GO:0006957 | 5 / 16 | 99.0× | 1.12e-9 | 2.48e-7 ✓ sig. |
| positive regulation of vascular endothelial growth factor production | GO:0010575 | 5 / 32 | 49.5× | 4.98e-8 | 6.76e-6 ✓ sig. |
| complement activation, classical pathway | GO:0006958 | 5 / 37 | 42.8× | 1.06e-7 | 1.27e-5 ✓ sig. |
| cellular response to lipopolysaccharide | GO:0071222 | 8 / 187 | 13.5× | 1.24e-7 | 1.44e-5 ✓ sig. |
| vascular endothelial growth factor production | GO:0010573 | 3 / 6 | 158× | 5.94e-7 | 5.41e-5 ✓ sig. |
| positive regulation of glial cell proliferation | GO:0060252 | 4 / 22 | 57.6× | 6.28e-7 | 5.67e-5 ✓ sig. |
| positive regulation of mitotic nuclear division | GO:0045840 | 4 / 29 | 43.7× | 2.01e-6 | 1.45e-4 ✓ sig. |
| liver regeneration | GO:0097421 | 4 / 29 | 43.7× | 2.01e-6 | 1.45e-4 ✓ sig. |
| negative regulation of heterotypic cell-cell adhesion | GO:0034115 | 3 / 11 | 86.4× | 4.84e-6 | 2.93e-4 ✓ sig. |
| cytolysis by host of symbiont cells | GO:0051838 | 3 / 11 | 86.4× | 4.84e-6 | 2.93e-4 ✓ sig. |
| acute-phase response | GO:0006953 | 4 / 37 | 34.2× | 5.48e-6 | 3.23e-4 ✓ sig. |
| activation of membrane attack complex | GO:0001905 | 3 / 13 | 73.1× | 8.36e-6 | 4.54e-4 ✓ sig. |
| positive regulation of heterotypic cell-cell adhesion | GO:0034116 | 3 / 13 | 73.1× | 8.36e-6 | 4.54e-4 ✓ sig. |
| positive regulation of nitric oxide biosynthetic process | GO:0045429 | 4 / 42 | 30.2× | 9.17e-6 | 4.89e-4 ✓ sig. |